Phase 2 study of BKM120 in patients with advanced esophagus cancer

Trial Profile

Phase 2 study of BKM120 in patients with advanced esophagus cancer

Discontinued
Phase of Trial: Phase II

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Buparlisib (Primary)
  • Indications Oesophageal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Jun 2017 Primary endpoint (Disease control rate) has been met, according to the results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 16 Mar 2017 Status changed from active, no longer recruiting to discontinued.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top